Current status of treatment for chronic hepatitis C virus infection

Drugs of Today

Volumn 48, Issue 3, 2012, Pages 219-231

  Talwani, R ^a   Gilliam, B L ^a   Rizza, S A ^b   Nehra, V ^b   Temesgen, Zelalem ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; BOCEPREVIR; CONTRACEPTIVE AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; ILLICIT DRUG; INTERLEUKIN 28; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

AGING; ALCOHOL CONSUMPTION; ANEMIA; ANUS PRURITUS; AUTOIMMUNE DISEASE; BLOOD TRANSFUSION; CANCER RISK; CLINICAL EVALUATION; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE DURATION; DISEASE SURVEILLANCE; DNA POLYMORPHISM; DRUG DESIGN; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESEARCH; DYSGEUSIA; ELASTOGRAPHY; ENZYME IMMUNOASSAY; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNIZATION; INSULIN RESISTANCE; IRRITABILITY; LABORATORY TEST; LEUKOPENIA; LIFE EXPECTANCY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; MACULOPAPULAR RASH; MENTAL DISEASE; MIXED INFECTION; NEEDLESTICK INJURY; OBESITY; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PATIENT CARE PLANNING; PATIENT MONITORING; PRACTICE GUIDELINE; PREGNANCY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; MONITORING, PHYSIOLOGIC; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84859705009     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.3.1740457     Document Type: Review

References (75)

1. Ghany, M.G., Strader, D.B., Thomas, D.L., Seeff, L.B. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009, 49(4): 1335-74.
2. Davis, G.L. Hepatitis C virus genotypes and quasispecies. Am J Med 1999, 107(6B): 21S-6S.
3. Alter, M.J. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007, 13(17): 2436-41. (Pubitemid 46929498)
4. Armstrong, G.L., Wasley, A., Simard, E.P., McQuillan, G.M., Kuhnert, W.L., Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 44(10): 705-14. (Pubitemid 46780630)
5. de Vries, M.J., Rijdt te, B., van Nieuwkerk, C.M.J. Genotype distribution amongst hepatitis C patients in The Netherlands. Neth J Med 2006, 64(4): 109-13.
6. Soriano, V., Puoti, M., Sulkowski, M., Cargnel, A., Benhamou, Y., Peters M. et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007, 21(9): 1073-8.
7. Kramer J.R., Giordano T.P., Souchek J., Richardson P., Hwang L-Y., El-Serag H.B. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005, 100(1): 56-63. (Pubitemid 41623269)
8. Rustgi, V.K. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007, 42(7): 513-21. (Pubitemid 47190067)
9. Di Bisceglie, A.M. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000, 31(4): 1014-18. (Pubitemid 30169951)
10. Freeman, A. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001, 34(4): 809-16. (Pubitemid 32928008)
11. Thein, H-H., Yi, Q., Dore, G.J., Krahn, M.D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008, 48(2): 418-31.
12. Benhamou, Y., Bochet, M., Di Martino V., Charlotte F. et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999, 30(4): 1054-58. (Pubitemid 29458296)
13. Bräu, N., Salvatore, M., Ríos-Bedoya, C.F. et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006, 44(1): 47-55. (Pubitemid 41772515)
14. Wise, M., Bialek, S., Finelli, L., Bell, B.P., Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2007, 47(4): 1128-35.
15. Hui, J.M., Sud, A., Farrell, G.C. et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. YGAST 2003, 125(6): 1695-04.
16. Ortiz, V., Berenguer, M., Rayon, J.M., Carrasco, D., Berenguer, J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002, 97(9): 2408-14.
17. Ferreira-Gonzalez, A., Shiffman, M.L. Use of diagnostic testing for managing hepatitis C virus infection. Semin Liver Dis 2004, 24(Suppl. 2): 9-18. (Pubitemid 39180701)
18. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998, 47(RR-19): 1-39.
19. Bruix, J., Sherman, M. Management of hepatocellular carcinoma: An update. Hepatology 2011, 53(3): 1020-2.
20. Seeff, L.B., Everson, G.T., Morgan, T.R. et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010, 8(10): 877-83.
21. Myers, R.P., De Torres, M., Imbert-Bismut, F. et al. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci 2003, 48(1): 146-53. (Pubitemid 36232774)
22. Rossi, E., Adams, L., Prins, A. et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003, 49(3): 450-4. (Pubitemid 36250205)
23. Halfon, P., Bourliere, M., Deydier, R. et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006, 101(3): 547-55. (Pubitemid 43340931)
24. Baranova, A., Lal, P., Birerdinc, A., Younossi, Z.M. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol 2011, 11: 91.
25. Cardoso, A-C., Carvalho-Filho, R.J., Marcellin, P. Transient elastography in chronic viral hepatitis: a critical appraisal. Gut 2011, 60(6): 759-64.
26. Arora, S., Thornton, K., Murata, G. et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011, 364(23): 2199-207.
27. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002, 123(6): 2082-99.
28. Lecube, A., Hernández, C., Simó, R., Esteban, J.I., Genescà, J. Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Am J Gastroenterol 2007, 102(10): 2189-95. (Pubitemid 47493841)
29. Bitetto, D., Fabris, C., Fornasiere, E. et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2010, 24(1): 43-50.
30. Ge, D., Fellay, J., Thompson, A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461(7262): 399-401.
31. Berenguer, J., Alvarez-Pellicer, J., Martín, P.M., López-Aldeguer, J., Von-Wichmann M.A., Quereda, C. et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009, 50(2): 407-13.
32. Cammà, C., Di Bona, D., Schepis, F., Heathcote, E.J., Zeuzem, S, Pockros, P.J. et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data. Hepatology 2004, 39(2): 333-42. (Pubitemid 38222174)
33. Bruno, S., Stroffolini, T., Colombo, M., Bollani, S., Benvegnù, L., Mazzella, G. et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007, 45(3): 579-87. (Pubitemid 46453759)
34. Veldt, B.J., Heathcote, E.J., Wedemeyer, H., Reichen, J., Hofmann, W.P., Zeuzem S., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007, 147(10): 677-84. (Pubitemid 351664462)
35. George S.L., Bacon B.R., Brunt, E.M., Mihindukulasuriya, K.L., Hoffmann, J., Di Bisceglie, A.M. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients. Hepatology 2009, 49(3): 729-38.
36. Fernández-Rodríguez, C.M., Alonso, S., Martinez, S.M., Forns, X., Sanchez-Tapias, J.M., Rincón, D. et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: Outcomes and factors predicting response. Am J Gastroenterol 2010, 105(10): 2164-72.
37. Maylin, S., Martinot-Peignoux, M., Ripault, M-P., Moucari, R., Cardoso, A-C., Boyer, N. et al. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int 2009, 29(4): 511-7.
38. Maylin, S., Martinot-Peignoux, M., Moucari, R., Boyer, N., Ripault, M-P., Cazals-Hatem, D. et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008, 135(3): 821-9.
39. Romeo, R., Pol, S., Berthelot, P., Brechot, C. Eradication of hepatitis C virus RNA after alpha-interferon therapy. Ann Intern Med 1994, 121(4): 276-7.
40. Pham, T.N.Q., MacParland, S.A., Mulrooney, P.M., Cooksley, H., Naoumov, N.V., Michalak, T.I. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004, 78(11): 5867-74. (Pubitemid 38661674)
41. Radkowski, M., Gallegos-Orozco, J.F, Jablonska, J., Colby, T.V., Walewska-Zielecka, B., Kubicka, J. et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005, 41(1): 106-14. (Pubitemid 40066388)
42. Castillo, I., Rodríguez-Iñigo, E., López-Alcorocho, J.M., Pardo, M., Bartolomé, J., Carreño, V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006, 43(10): 1277-83. (Pubitemid 44706453)
43. Sarrazin, C., Teuber, G., Kokka, R., Rabenau, H., Zeuzem, S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000, 32(4, Pt. 1): 818-23.
44. Jeffers, L.J., Cassidy, W., Howell, C.D., Hu, S., Reddy, K.R. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004, 39(6): 1702-8. (Pubitemid 38702672)
45. Muir, A.J., Bornstein, J.D., Killenberg, P.G., Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350(22): 2265-71. (Pubitemid 38669209)
46. Carlsson, T., Reichard, O., Norkrans, G. et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 2005, 12(5): 473-80. (Pubitemid 41224250)
47. Bonardi, R., Tabone, M., Manca, A., Pellicano, R., Ciancio, A., Rizzetto, M. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Biomed Pharmacother 2011, 65(4): 303-6.
48. Chung, R.T., Andersen, J., Volberding, P. et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351(5): 451-9. (Pubitemid 38988594)
49. Fried, M.W., Shiffman, M.L., Reddy, K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13): 975-92.
50. Rizza, S.A., Talwani, R., Nehra, V., Temesgen, Z. Boceprevir. Drugs Today (Barc) 2011, 47(10): 743-51.
51. Nehra, V., Rizza, S.A., Talwani, R., Temesgen, Z. Telaprevir: looking for a sustained virologic response in hepatitis C virus infection. Drugs Today (Barc) 2011, 47(11): 829-37.
52. Manns, M.P., McHutchison, J.G., Gordon, S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286): 958-65. (Pubitemid 32913521)
53. Hadziyannis, S.J., Sette, H., Morgan, T.R. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140(5): 346-55.
54. Ghany, M.G., Nelson, D.R., Strader, D.B., Thomas, D.L., Seeff, L.B. American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54(4): 1433-44.
55. Boceprevir [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2011.
56. Telaprevir [package insert]. Boston, MA: Vertex Pharmaceuticals; 2011.
57. Jacobson, I.M., Brown, R.S., Freilich, B. et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007, 46(4): 971-81.
58. Roberts, S.K., Andreone, P., Pol, S. et al. Impact of anemia and ribavirin dose reduction on SVR to a telaprevir-based regimen in patients with genotype 1 and prior peginterferon/ribavirin treatment failure in the phase III REALIZE study. Hepatology [62nd Annu Meet Am Assoc Study Liver Dis (Nov 4-8, San Francisco) 2011] 2011, 54(4, Suppl.): Abst 1368.
59. Di Bisceglie, A.M., Stoddard, A.M., Dienstag, J.L. et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011, 53(4): 1100-8.
60. Bacon, B.R., Gordon, S.C., Lawitz, E. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13): 1207-17.
61. Zeuzem, S., Andreone, P., Pol, S. et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364(25): 2417-28.
62. Vierling, J.M., Flamm, S.L., Gordon, S.C. et al. Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: The PROVIDE study. Hepatology [62nd Annu Meet Am Assoc Study Liver Dis (Nov 4-8, San Francisco) 2011] 2011, 54(4, Suppl.): Abst 931.
63. Bressanelli, S., Tomei, L., Roussel, A., Incitti, I., Vitale, R.L., Mathieu, M. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A 1999, 96(23): 13034-9.
64. Bartenschlager, R., Lohmann, V. Replication of hepatitis C virus. J Gen Virol 2000, 81(Pt. 7): 1631-48. (Pubitemid 30427068)
65. Appel, N., Schaller, T., Penin, F., Bartenschlager, R. From structure to function: new insights into hepatitis C virus RNA replication. J Biol Chem 2006, 281(15): 9833-6. (Pubitemid 43864513)
66. Moriishi, K., Matsuura, Y. Host factors involved in the replication of hepatitis C virus. Rev Med Virol 2007, 17(5): 343-54. (Pubitemid 47425871)
67. Einav, S., Gerber, D., Bryson, P.D., Sklan, E.H., Elazar, M., Maerkl, S.J. et al. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol 2008, 26(9): 1019-27.
68. Lemon, S.M., McKeating, J.A., Pietschmann, T., Frick, D.N., Glenn, J.S., Tellinghuisen T.L. et al. Development of novel therapies for hepatitis C. Antiviral Res 2010, 86(1): 79-92.
69. Yang, P.L., Gao, M., Lin, K., Liu, Q., Villareal, V.A. Anti-HCV drugs in the pipeline. Curr Opin Virol 2011, 1(6): 607-16.
70. He, Y., Duan, W., Tan, S-L. Emerging host cell targets for hepatitis C therapy. Drug Discov Today 2007, 12(5-6): 209-17.
71. Knodell, R.G., Ishak, K.G., Black, W.C. et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1(5): 431-5. (Pubitemid 12218164)
72. Craxì, A. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011, 55(2): 245-64.
73. Batts, K.P., Ludwig, J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995, 19(12): 1409-17.
74. Bedossa, P., Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24(2): 289-93. (Pubitemid 26260021)
75. Ishak, K., Baptista, A., Bianchi, L. et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22(6): 696-9.